GO
Loading...

Takeover Bids

More

  • Allergan rejects Valeant Pharma's takeover bid Monday, 12 May 2014 | 7:13 AM ET

    May 12- U.S. medical firm Allergan Inc rejected the unsolicited takeover offer from Valeant Pharmaceuticals International Inc, saying it substantially undervalued the company. Canada's Valeant said on Aug. 22 that it and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Allergan.

  • MILAN, May 12- Australia's Ramsay Health Care is aiming to gain a majority stake in French private healthcare group Generale de Sante via a joint bid that values the company at around 910 million euros.

  • BUSINESS-NEWS-SCHEDULE AT 1830 GMT / 2:30 PM ET Wednesday, 7 May 2014 | 2:42 PM ET

    British PM tells Pfizer wants more commitments for AstraZeneca deal. LONDON- Prime Minister David Cameron says Britain wants more commitments from Pfizer on its $106 billion takeover bid for British pharmaceutical company AstraZeneca.

  • *UK could use public interest powers, Business Secretary says. *Lawmakers summon Pfizer, AstraZeneca bosses over takeover bid. LONDON, May 6- Britain could use its public interest powers to intervene in U.S. drugmaker Pfizer's $106- billion takeover bid for British pharmaceutical firm AstraZeneca, Business Secretary Vince Cable said on Tuesday.

  • BRITISH BUSINESS SECRETARY CABLE SAYS PFIZER TAKEOVER BID FOR ASTRAZENICA IS A MATTER FOR SHAREHOLDERS OF THE COMPANIES.

  • LONDON, May 6- British lawmakers on Tuesday summoned bosses of U.S. drugmaker Pfizer to explain a $106 billion takeover bid for pharmaceutical firm AstraZeneca which has raised fears over UK jobs, research and intellectual property.

  • LAUNCESTON, Australia, May 6- Baosteel Resources' motivation for a hostile $1 billion takeover of Australia's Aquila Resources is to jumpstart a stalled iron ore project. Baosteel is seeking to gain control of Aquila in order to get the junior company's half-share of the $7 billion West Pilbara Iron Ore Project, located in the north of Western Australia state.

  • Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."

  • Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.

  • CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.

  • May 5- Sterigenics, a sterilization services provider owned by private equity firm GTCR LLC, raised its buyout offer for Nordion Inc to $758 million from $727 million on Monday, after the Canadian medical isotope supplier received a rival bid from an unnamed buyer.

  • *Aurizon sees West Pilbara Iron Ore producing from 2017-18. Monday's unsolicited A $1.14 billion offer to take over Aquila Resources Ltd could open up a new Australian iron ore export region to supply Asian steelmakers, by jumpstarting the $7 billion West Pilbara Iron Ore project, half-owned by Aquila.

  • SYDNEY, May 5- Australian gas firm WestSide Corp Ltd on Monday rejected as undervalued a takeover offer from China's diversified energy company Landbridge Group Co Ltd that valued the company at A $177.6 million.

  • LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, opposition Labour party leader Ed Miliband said on Sunday. AstraZeneca rejected a 63 billion pound takeover bid from Pfizer on Friday, but the U.S. firm is expected to pursue its interest.

  • AstraZeneca rejects new Pfizer bid     Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • *AstraZeneca board rejects sweetened 50 stg/ shr offer. LONDON, May 2- U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.

  • *Deutsche Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,187.72 points. Both the FTSEurofirst 300 and the Euro STOXX 50 have gained more than 2 percent since the start of 2014..

  • Astrazeneca rejects latest Pfizer approach Friday, 2 May 2014 | 5:59 AM ET

    LONDON, May 2- AstraZeneca's board said on Friday it had rejected an improved $106 billion takeover offer from U.S. drugmaker Pfizer, saying the bid which was announced just hours ago undervalued the firm.

  • Takeover activity keeps European shares steady Friday, 2 May 2014 | 4:11 AM ET

    *Dt Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,188.48 points. On Friday, Deutsche Telekom rose 1.9 percent, after Reuters reported that U.S. rival Sprint had met with banks ahead of a planned bid for T-Mobile US, which is 67 percent owned by Deutsche Telekom.

  • AstraZeneca says board will review Pfizer offer Friday, 2 May 2014 | 2:42 AM ET

    LONDON, May 2- AstraZeneca's board will be reviewing a sweetened takeover offer from Pfizer but the company has no further comment at this stage, a spokeswoman for the British drugmaker said on Friday.